Table 5.
Distribution of 277 ADEs identified in 189 patients, listed according to frequency
| Adverse drug event | Number of patients with ADE (% of Pptients with an ADE) |
|---|---|
| Gastrointestinal symptoms | 34 (18.0) |
| Electrolyte disorders | 27 (14.3) |
| Hypersensitivity reactions | 24 (12.7) |
| Blood disorders | 22 (11.6) |
| Renal impairment | 16 (8.5) |
| Hemodynamic instability | 15 (7.9) |
| Over-anticoagulation | 15 (7.9) |
| Bleeding | 14 (7.4) |
| Infections | 14 (7.4) |
| Hepatopathy | 13 (6.9) |
| Altered level of consciousness | 9 (4.8) |
| Metabolic disorders | 9 (4.8) |
| Dizziness | 7 (3.7) |
| Mucositis | 5 (2.6) |
| Confusion | 4 (2.1) |
| Movement disorders | 3 (1.6) |
| Oedema | 3 (1.6) |
| Respiratory depression | 3 (1.6) |
| Cephalgia | 2 (1.1) |
| Neuropathy | 2 (1.1) |
| Pancreatitis | 2 (1.1) |
| Weight disorders | 2 (1.1) |
| Arrhythmia | 1 (0.5) |
| Visual disturbance | 1 (0.5) |
| Insomnia | 1 (0.5) |
| Muscle disorder | 1 (0.5) |
| Pain at Injection site | 1 (0.5) |
| Pleural effusion | 1 (0.5) |
| Progressive multifocal leukoencephalopathy | 1 (0.5) |
| Pupillary disorder | 1 (0.5) |
| Urinary retention | 1 (0.5) |
| Others | 23 (12) |